Biofrontera (BFRI) Q2 FY26 earnings call

Biofrontera delivered its strongest second quarter and first half as a standalone U.S. business, driven by robust Ameluz sales and significantly improved gross margins following a strategic transaction. Despite an ITC ruling impacting the RhodoLED XL lamp, the company is pursuing remediation and legal avenues while focusing on pipeline advancements for superficial basal cell carcinoma and actinic keratosis label expansion to drive future growth through its existing commercial infrastructure.